Aa
Spring Bank Pharmaceuticals Phase 2 Clinical Trial
Spring Bank Pharmaceuticals Announces Clinical Trial Collaboration with Gilead Sciences for Hepatitis B (HBV) Phase 2 Clinical Trial
MILFORD, Mass., Nov. 19, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced a clinical trial collaboration with Gilead Sciences for a Hepatitis B (HBV) Phase 2 clinical study with Spring Bank's SB 9200 in combination with Viread® (tenofovir disoproxil fumarate) for HBV patients.
Dr. Nezam Afdhal, Spring Bank's Chief Medical Officer, said "Although medications like Viread® are excellent at suppressing HBV replication, 'HBV cure' has remained elusive. We are very excited to move SB 9200 into Phase 2 clinical development in collaboration with Gilead. We believe that SB 9200 has the potential to be an important advance in the treatment of HBV patients, providing the potential for clearance of HBsAg, or functional cure, and will be studied both alone and in combination with Viread®."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of orally bioavailable therapeutics based on its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate the host cellular proteins, RIG I and NOD 2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 can play an important role in antiviral therapy by modulating host immune response to fight viral infections such as HBV, HCV and RSV.
MILFORD, Mass., Nov. 19, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced a clinical trial collaboration with Gilead Sciences for a Hepatitis B (HBV) Phase 2 clinical study with Spring Bank's SB 9200 in combination with Viread® (tenofovir disoproxil fumarate) for HBV patients.
Dr. Nezam Afdhal, Spring Bank's Chief Medical Officer, said "Although medications like Viread® are excellent at suppressing HBV replication, 'HBV cure' has remained elusive. We are very excited to move SB 9200 into Phase 2 clinical development in collaboration with Gilead. We believe that SB 9200 has the potential to be an important advance in the treatment of HBV patients, providing the potential for clearance of HBsAg, or functional cure, and will be studied both alone and in combination with Viread®."
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of orally bioavailable therapeutics based on its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate the host cellular proteins, RIG I and NOD 2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 can play an important role in antiviral therapy by modulating host immune response to fight viral infections such as HBV, HCV and RSV.
I reckon its most probable TAF will get approved in the not so distant future.
TAF is not approved by the FDA yet, though the plan will target for them to do so soon. I suspect this is just a way for them to continue treatment with TDF "just in case" TAF does not get approve and the TDF patent expires.
Maybe they are not allowed by the FDA to combine two experimental drugs at once.This is the FDAs way of reducing risks.
Thanks
Just a thought why trial it with tdf and not taf?
As obviously taf is gileads new nuc no.
So if they were going to attempt a combo one within patent would be better for business no?
Just a thought why trial it with tdf and not taf?
As obviously taf is gileads new nuc no.
So if they were going to attempt a combo one within patent would be better for business no?
The companys drug is an activator of the cytocolic RIg and NOD proteins, which are activators of intracellular innate immunity.
Studies in infected wookchucks have shown a decent effectiveness in reducing viral load and some activity to reduce surface antigen.
The woodhcuck efficacy was however less intense than the GS9620, a TLR7 stimulator, which is another part of innate immunity sensors.
There was clear activation of interferon response genes and some interferon level increase with this drug in the animal studies.
In summary this is a similar approach than the gs9620 study, that has thus far disappointed in the human trials.
Since this activates different innate receptors, it might work better, but i would be truly surprised if this drug would be able to dramatically lower the hbsag in combo with Viread as seems to be the plan.
Studies in infected wookchucks have shown a decent effectiveness in reducing viral load and some activity to reduce surface antigen.
The woodhcuck efficacy was however less intense than the GS9620, a TLR7 stimulator, which is another part of innate immunity sensors.
There was clear activation of interferon response genes and some interferon level increase with this drug in the animal studies.
In summary this is a similar approach than the gs9620 study, that has thus far disappointed in the human trials.
Since this activates different innate receptors, it might work better, but i would be truly surprised if this drug would be able to dramatically lower the hbsag in combo with Viread as seems to be the plan.
Please as ever your opinion would be greatly appreciated be me and many im sure.
Is this a suprising move from Gilead?
Is this a suprising move from Gilead?
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
